Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Vertex Pharmaceuticals trades at $500.94 and has moved in lockstep with the market. Its shares have returned 5.5% over the ...

BTIG analyst Mark Massaro lowered the firm’s price target on MaxCyte (MXCT) to $6 from $8 and keeps a Buy rating on the shares after its Q4 ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). In a filing disclosed on March 09th, the Representative disclosed that they had ...

Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA ...

Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

AbbVie, Danaher, Thermo Fisher Scientific, Cognizant Technology Solutions, and Vertex Pharmaceuticals are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options become available today, for the April 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...